Work

Obecabtagene autoleucel (obe-cel), a CD19-targeting chimeric antigen receptor (CAR) T-cell therapy, in patients with severe, refractory systemic lupus erythematosus (SLE) in the Phase I CARLYSLE study: Initial safety, preliminary efficacy, pharmacokinetics, and biomarker results

Year: 2025

Type: conference-abstract

Source: Blood

DOI: 10.1182/blood-2025-815

Authors: Claire Roddie, Maria Leandro, Ben Parker, Eleni Tholouli, David Jayne, Ben Uttenthal, Josefina Cortés-Hernández, Pere Barba, José Andrés Román Ivorra, Yanqing Hu, Wolfram Brugger, Silvia Basilico, Davide Germano, Ruth Pepper

Institutions: University College Hospital, University College London, Manchester Royal Infirmary, NIHR Manchester Clinical Research Facility, Cambridge University Hospitals NHS Foundation Trust, Universitat Autònoma de Barcelona, Vall d'Hebron Hospital Universitari, Hospital Universitari i Politècnic La Fe, The Royal Free Hospital

Language: English

Topic: CAR-T cell therapy research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4417017289

Cites:

Cited by:

Related to: